15 research outputs found
Novel and Emerging Therapies for Inflammatory Bowel Disease.
Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn\u27s disease are chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic manifestations. Despite the availability of current biologics, such as anti-tumor necrosis factor (anti-TNF), anti-integrins, anti-interleukins and small molecules such as tofacitinib, the rates of primary and secondary treatment failure remain high in IBD. This highlights the importance of continued development of new therapeutic targets and modifications of existing ones to improve the treatment response rates and to also improve the safety profile and tolerability of these medications. In this review we will discuss novel treatment target agents including selective janus kinase (JAK) inhibitors, anti-interleukin (IL) (IL-12/IL-23), leukocyte trafficking/migrating inhibitors (such as sphingosine-1-phosphate receptor modulator) and other small molecules currently in development
Sa1292 Readmission Rates in Patients With Inflammatory Bowel Disease Following an Admission for an Acute Flare of Disease
777 Effect of Ustekinumab Dose Escalation on Recapturing Clinical Response in Patients With Crohn's Disease
Improving Preventive Care in patients with Improving Preventive Care in Patients with Inflammatory Bowel Disease through Use of a Standardized Checklist Tool
Study Aims Improve communication to referring PCP of the preventive care screening needs for IBD patients seen in the ambulatory setting. Implement system wide change through the use of a progressively modified EPIC based smart tool integrated directly into our provider notes. Increase adherence to guidelines for immunization, cancer screening, infectious screening, osteoporosis screening (DEXA scans), and smoking cessation counseling.https://jdc.jefferson.edu/patientsafetyposters/1107/thumbnail.jp
Ventricular septal defect and bivalvular endocarditis
A 63-year-old man presented with generalized fatigue, chills, malaise, dyspnea, intermittent fevers, and 50-pound weight loss of 4 months′ duration. Blood cultures were positive for pan-sensitive Streptococcus anginosus. Transesophageal echocardiography showed an 11 mm × 3 mm mobile mass attached to the mitral valve, a 16 mm × 16 mm mobile mass attached to the pulmonary valve, and a small membranous ventricular septal defect. The patient received 12 weeks of intravenous (IV) antibiotics with eventual resolution of the masses. Multi-valve endocarditis involving both the left and right chambers is rarely reported without prior history of IV drug use or infective endocarditis. Our case emphasizes the importance of careful assessment for ventricular septal defects or extra-cardiac shunts in individuals who present with simultaneous right and left-sided endocarditis